InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Explore the full record of transactions filed by Karen AIACH, Chief Executive Officer. Director active across 1 company, notably LYSOGENE. Aggregated, 1 reports have been published. Breakdown: 1 buy · 0 sell. Total volume traded: €357k. Activity tracked since 2 June 2022. The latest transaction was filed on 2 June 2022 (Acquisition). Regulator: AMF. The full history is openly available.
1 of 1 declaration
Karen Aiach is the Chairman & CEO of LYSOGENE. She leads the company's operations and oversees the implementation of its strategy. Her expertise in the biopharmaceutical field is an asset for developing new solutions.